Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy

Johannes Pöhlmann,1 Roberta Montagnoli,2 Giusi Lastoria,3 Witesh Parekh,4 Marie Markert,5 Barnaby Hunt1 1Health Economics, Ossian Health Economics and Communications, Basel 4051, Switzerland; 2External Affairs-Region Europe, Novo Nordisk SpA, Rome IT00144, Italy; 3Medical Advice, Novo Nordi...

Full description

Bibliographic Details
Main Authors: Pöhlmann J, Montagnoli R, Lastoria G, Parekh W, Markert M, Hunt B
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Cost-effectiveness
Fixed-ratio combination
IDegLira
iGlarLixi
Italy
Type 2 diabetes
Online Access:https://www.dovepress.com/value-for-money-in-the-treatment-of-patients-with-type-2-diabetes-mell-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/value-for-money-in-the-treatment-of-patients-with-type-2-diabetes-mell-peer-reviewed-article-CEOR

Similar Items